AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday

Print Email

Earnings season is now in full swing, and we have put together a preview of some of the world’s largest biotechnology and pharmaceutical companies reporting their earnings on Thursday. With the markets running red-hot right now, it is no doubt that health care stocks are some that can benefit the most from this rising tide.

Over the past five, 10 and 20 years, the life sciences and bioproduction segments have outperformed the S&P 500 more often than not. Recently, we took a look at what one key analyst had to say about other companies in this segment that could continue to outperform the broad markets going forward.

Here we have included the Thomson Reuters consensus estimates for each stock, as well as some color and a recent trading history and consensus target for each stock.

AbbVie Inc. (NYSE: ABBV) is scheduled to report its first-quarter results before the markets open. The consensus estimates are $1.26 in earnings per share (EPS) and $6.48 billion in revenue. Shares were last seen at $65.88. The consensus price target is $71.28, and the 52-week range is $55.06 to $68.12.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) also is set to share its latest quarterly earnings in the morning. The consensus estimates call for a $1.23 in EPS on $827.2 million in revenue. Shares were at $122.88 on Wednesday, in a 52-week range of $109.12 to $157.02. The consensus price target is $161.70.

Bristol-Myers Squibb Co. (NYSE: BMY) is expected to reveal its first-quarter results early in the day as well. The consensus forecast calls for $0.74 in EPS and $4.72 billion in revenue. The stock recently traded at $54.59. The consensus price target is $55.76, and the 52-week range is $46.01 to $77.12.

And Celgene Corp. (NASDAQ: CELG) also will to share its latest quarterly earnings Thursday morning. The consensus estimates call for $1.64 in EPS and $3.04 billion in revenue. Shares were last trading at $125.85, in a 52-week range of $94.42 to $127.64. The consensus price target is $140.04.